In addition, integrins and focal adhesion proteins modulate treatment resistance in a variety of tumour cells, including glioma, breast cancer and uroepithelial carcinoma, through interactions with growth factor (GF) receptors such as epidermal growth factor receptor (EGFR) [9–11]. Here, EGFR is linked to urothelial carcinoma.